Rankings
▼
Calendar
AXSM
Axsome Therapeutics, Inc.
$8B
Q3 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$21M
Net Income
-$23M
EPS (Diluted)
$-0.61
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$16M
Free Cash Flow
-$16M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$204M
Total Liabilities
$68M
Stockholders' Equity
$135M
Cash & Equivalents
$202M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$21M
-$19M
-11.5%
Net Income
-$23M
-$19M
-19.8%
← FY 2020
All Quarters
Q4 2020 →
AXSM Q3 2020 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena